 SOUTH SAN FRANCISCO, Calif., Feb. 11, 2021 GLOBE NEWSWIRE -- Catalyst Biosciences, Inc. NASDAQ:CBIO the Company today announced that in connection with its previously announced public offering of its common stock, the underwriters partially exercised and closed their over-allotment option to purchase an additional 485,000 shares of the Companys common stock, offered at a price of 5.75 per share to the public. The Company received approximately 2.8 million in additional gross proceeds from the sale of these shares, before deducting underwriting discounts and commissions and other estimated offering expenses payable by the Company. All of the shares in the offering were sold by the Company. 